Generated by AI
Sana Biotechnology Inc. is a biotechnology company focused on creating and delivering engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms designed to address serious diseases with unmet treatment needs, including type 1 diabetes, B cell-mediated autoimmune diseases, oncology, and other immune-related conditions. Its work centers on modifying, replacing, or repairing cells to support next-generation therapeutic approaches, with research and development spanning cell therapy, gene delivery, and immune evasion technologies. Sana Biotechnology operates as a clinical-stage company and does not yet market approved commercial therapies, making its role in the market primarily centered on innovation, pipeline development, and translational research. Headquartered in Seattle, Washington, the company is part of the broader biotechnology sector, where engineered-cell platforms are an important area of active drug development.
Website188 East Blaine Street
Seattle, WA, 98102
United States
The latest articles about SANA.
Investing.com -- Guggenheim Securities has identified Surrozen, Inc. as its top pick in the biotechnology sector, assigning a Buy rating with a price target of $42.00. The firm hosted management from Surrozen to discuss recent developments in retinal vascular disease treatments and the company’s clinical pipeline.
Summary of Nov 13's posts. Generated by AI.
Summary of Jun 16's posts. Generated by AI.
Detailed price information for Sana Biotechnology Inc (SANA-Q) from The Globe and Mail including charting and trades.
Summary of Oct 16's posts. Generated by AI.
Investors talking about SANA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.